Corvus Pharmaceuticals Inc’s recent filing unveils that its Director ORBIMED ADVISORS LLC unloaded Company’s shares for reported $4.89 million on Jun 27 ’25. In the deal valued at $4.16 per share,1,176,332 shares were sold. As a result of this transaction, ORBIMED ADVISORS LLC now holds 7,165,006 shares worth roughly $55.03 million.
Then, Thompson Peter A. sold 1,176,332 shares, generating $4,891,894 in total proceeds. Upon selling the shares at $4.16, the Director now owns 7,165,006 shares.
Barclays initiated its Corvus Pharmaceuticals Inc [CRVS] rating to an Overweight in a research note published on October 13, 2025; the price target was $16. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Oppenheimer began covering CRVS with “an Outperform” recommendation on August 18, 2023.
Price Performance Review of CRVS
On Monday, Corvus Pharmaceuticals Inc [NASDAQ:CRVS] saw its stock fall -4.48% to $7.68. Over the last five days, the stock has lost -2.29%. Corvus Pharmaceuticals Inc shares have fallen nearly -12.73% since the year began. Nevertheless, the stocks have risen 43.55% over the past one year. While a 52-week high of $10.00 was reached on 10/31/25, a 52-week low of $2.54 was recorded on 04/09/25.
Levels Of Support And Resistance For CRVS Stock
The 24-hour chart illustrates a support level at 7.47, which if violated will result in even more drops to 7.26. On the upside, there is a resistance level at 7.94. A further resistance level may holdings at 8.20.
How much short interest is there in Corvus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Corvus Pharmaceuticals Inc stocks on 2025-10-15, dropping by -0.84 million shares to a total of 8.83 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 9.67 million shares. There was a decline of -9.48%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 27, 2021 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $10 price target.
